Impact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancer

Journal of the Egyptian National Cancer Institute

Volumn 27, Issue 3, 2015, Pages 155-159

  Mohammed, Amrallah A ^a,b   EL Tanni, Hani ^a   Ghanem, Hafez M ^a   Farooq, Mian U ^a   El Saify, Amr M ^a   Al Zahrani, Abdullah S ^a   EL Shentenawy, Ayman ^c   EL Khatib, Hani M ^a  

^a King Abdullah Medical City Holy Capital ^*  (Saudi Arabia)

^b ZAGAZIG UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Cancer specific survival; Metastatic prostate cancer; Obesity

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BONE METASTASIS; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; VISCERAL METASTASIS; BONE NEOPLASMS; CANCER GRADING; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BONE NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; OBESITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938955763     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2015.07.001     Document Type: Article

References (29)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Kawahara T., Miyoshi Y., Sekiguchi Z., Sano F., Hayashi N., Teranishi J., et al. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PLoS One 2012, 7(10):e48186. 10.1371/journal.pone.0048186.
3. Rodriguez C., Freedland S., Deka A., Jacobs E., McCullough M., Patel A., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:63-69.
4. Wright M., Chang S., Schatzkin A., Albanes D., Kipnis V., Mouw T., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007, 109:675-684.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
6. Amling C.L., Blute M.L., Lerner S.E., Bergstralh E.J., Bostwick D.G., Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998, 73:401-406.
7. Haslam D., James W.P.T. Obesity. Lancet 2005, 366:1197-1209.
8. Capitanio U., Suardi N., Briganti A., Gallina A., Abdollah F., Lughezzani G., et al. Influence of obesity on tumour volume in patients with prostate cancer. BJU Int 2012, 109:678-684.
9. Rodriguez C., Patel A., Calle E., Jacobs E., Chao A., Thun M. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001, 10:345-353.
10. Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer 2007, 110:2691-2699.
11. Gong Z., Agalliu I., Lin D.W., Stanford J.L., Kristal A.R. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007, 109:1192-1202.
12. Siddiqui S.A., Inman B.A., Sengupta S., Slezak J.M., Bergstralh E.J., Leibovich B.C., et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer 2006, 107:521-529.
13. Magheli A., Rais-Bahrami S., Trock B.J., Humphreys E.B., Partin A.W., Han M., et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 2008, 72:1246-1251.
14. Irani J., Lefebvre O., Murat F., Dahmani L., Dore B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int 2003, 91:482-484.
15. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006, 355:763-778.
16. Freedland S.J., Aronson W.J., Kane C.J., Presti J.C., Amling C.L., Elashoff D., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004, 22:446-453.
17. Park J.M., Nam J.S., Na W., Oh J.J., Lee S., Hong S.K., et al. Prognostic value of body mass index in Korean patients with castration-resistant prostate cancer Korean. J Urol 2012, 53:761-765.
18. Strom S.S., Kamat A.M., Gruschkus S.K., Gu Y., Wen S., Cheung M.R., et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006, 107:631-639.
19. Halabi S., Ou S.S., Vogelzang N.J., Small E.J. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 2007, 110:1478-1484.
20. Ma J., Li H., Giovannucci E., Mucci L., Qiu W., Nguyen P.L., et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008, 9:1039-1047.
21. Li H., Stampfer M.J., Mucci L., Rifai N., Qiu W., Kurth T., et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010, 56:34-43.
22. Platz E.A., Leitzmann M.F., Rifai N., Kantoff P.W., Chen Y.C., Stampfer M.J., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005, 14:1262-1269.
23. Severi G., Morris H.A., MacInnis R.J., English D.R., Tilley W., Hopper J.L., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:86-91.
24. Chan J.M., Stampfer M.J., Ma J., Gann P., Gaziano J.M., Pollak M., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002, 94:1099-1106.
25. Freedland S.J., Sun L., Kane C.J., Presti J.C., Terris M.K., Amling C.L., et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int 2008, 102:969-974.
26. Banez L.L., Hamilton R.J., Partin A.W., Vollmer R.T., Sun L., Rodriguez C., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007, 298:2275-2280.
27. Lee I.M., Sesso H., Paffenbarger R. A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control 2001, 12:187-193.
28. Nilson L., Vatten L. Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. Cancer Causes Control 1999, 10:269-275.
29. Giovannucci E., Rimm E.B., Liu Y., Leitzmann M., Wu K., Stampfer M.J., Stampfer M.J., et al. Body mass index and risk of prostate cancer in US health professionals. J Natl Cancer Inst 2003, 95:1240-1244.